Reply to: The Association Between Cognitive Decline and Bone Loss and Fracture Risk Is Not Affected by Medication With Anticholinergic Effect

for the CaMOS Research Group

doi:10.1002/jbmr.4530

Reply to: The Association Between Cognitive Decline and Bone Loss and Fracture Risk Is Not Affected by Medication With Anticholinergic Effect

for the CaMOS Research Group

Medicine

Medicine

Producción científica: Contribución a una revista › Carta › revisión exhaustiva

Idioma original	English
Páginas (desde-hasta)	1075-1076
Número de páginas	2
Publicación	Journal of Bone and Mineral Research
Volumen	37
N.º	5
DOI	https://doi.org/10.1002/jbmr.4530
Estado	Published - may. 2022

Nota bibliográfica

Funding Information:
DB, TT, TvG, CB, DG, RGJ, LL, GJA, LBS, RC, CJS, CSK, SMK and JCP have no competing interests to declare. JDA has received research grants and/or personal fees from Amgen, Eli Lilly, Merck, Actavis and AgNovos. JvdB has received grants and/or personal fees from Amgen, MSD, and Eli Lilly. JAE has consulted for and/or received research funding from Amgen, deCode, Merck Sharp and Dohme, and Sanofi‐Aventis. PG was advisory member for Amgen, has received speaker fee and/or research grants from Amgen, Pfizer, MSD, UCB, Abbott, Lilly, BMS, Novartis, Roche and Will Pharma. DAH has consulted for and/or received speaker fee and /or research funding from Amgen, Merck and Eli Lilly. TVN has received honoraria for consulting and symposia from Merck Sharp and Dohme, Roche, Servier, Sanofi‐Aventis, and Novartis. JRC has consulted for and/or given educational talks for Merck Sharp and Dohme, Amgen, Actavis, Bayer and Sanofi‐Aventis.

ASJC Scopus Subject Areas

Endocrinology, Diabetes and Metabolism
Orthopedics and Sports Medicine

PubMed: MeSH publication types

Letter
Comment

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1002/jbmr.4530

Otros archivos y enlaces

Citar esto

@article{bf5483bc02c8453da1fc034a8fe8ba91,

title = "Reply to: The Association Between Cognitive Decline and Bone Loss and Fracture Risk Is Not Affected by Medication With Anticholinergic Effect",

author = "{for the CaMOS Research Group} and Dana Bliuc and Thach Tran and Adachi, {Jonathan D.} and Atkins, {Gerald J.} and Claudie Berger and {van den Bergh}, Joop and Roberto Cappai and Eisman, {John A.} and {van Geel}, Tineke and Piet Geusens and David Goltzman and Hanley, {David A.} and Robert Josse and Stephanie Kaiser and Kovacs, {Christopher S.} and Lisa Langsetmo and Prior, {Jerilynn C.} and Nguyen, {Tuan V.} and Solomon, {Lucian B.} and Catherine Stapledon and Center, {Jacqueline R.}",

note = "Funding Information: DB, TT, TvG, CB, DG, RGJ, LL, GJA, LBS, RC, CJS, CSK, SMK and JCP have no competing interests to declare. JDA has received research grants and/or personal fees from Amgen, Eli Lilly, Merck, Actavis and AgNovos. JvdB has received grants and/or personal fees from Amgen, MSD, and Eli Lilly. JAE has consulted for and/or received research funding from Amgen, deCode, Merck Sharp and Dohme, and Sanofi‐Aventis. PG was advisory member for Amgen, has received speaker fee and/or research grants from Amgen, Pfizer, MSD, UCB, Abbott, Lilly, BMS, Novartis, Roche and Will Pharma. DAH has consulted for and/or received speaker fee and /or research funding from Amgen, Merck and Eli Lilly. TVN has received honoraria for consulting and symposia from Merck Sharp and Dohme, Roche, Servier, Sanofi‐Aventis, and Novartis. JRC has consulted for and/or given educational talks for Merck Sharp and Dohme, Amgen, Actavis, Bayer and Sanofi‐Aventis.",

year = "2022",

month = may,

doi = "10.1002/jbmr.4530",

language = "English",

volume = "37",

pages = "1075--1076",

journal = "Journal of Bone and Mineral Research",

issn = "0884-0431",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Reply to

T2 - The Association Between Cognitive Decline and Bone Loss and Fracture Risk Is Not Affected by Medication With Anticholinergic Effect

AU - for the CaMOS Research Group

AU - Bliuc, Dana

AU - Tran, Thach

AU - Adachi, Jonathan D.

AU - Atkins, Gerald J.

AU - Berger, Claudie

AU - van den Bergh, Joop

AU - Cappai, Roberto

AU - Eisman, John A.

AU - van Geel, Tineke

AU - Geusens, Piet

AU - Goltzman, David

AU - Hanley, David A.

AU - Josse, Robert

AU - Kaiser, Stephanie

AU - Kovacs, Christopher S.

AU - Langsetmo, Lisa

AU - Prior, Jerilynn C.

AU - Nguyen, Tuan V.

AU - Solomon, Lucian B.

AU - Stapledon, Catherine

AU - Center, Jacqueline R.

N1 - Funding Information: DB, TT, TvG, CB, DG, RGJ, LL, GJA, LBS, RC, CJS, CSK, SMK and JCP have no competing interests to declare. JDA has received research grants and/or personal fees from Amgen, Eli Lilly, Merck, Actavis and AgNovos. JvdB has received grants and/or personal fees from Amgen, MSD, and Eli Lilly. JAE has consulted for and/or received research funding from Amgen, deCode, Merck Sharp and Dohme, and Sanofi‐Aventis. PG was advisory member for Amgen, has received speaker fee and/or research grants from Amgen, Pfizer, MSD, UCB, Abbott, Lilly, BMS, Novartis, Roche and Will Pharma. DAH has consulted for and/or received speaker fee and /or research funding from Amgen, Merck and Eli Lilly. TVN has received honoraria for consulting and symposia from Merck Sharp and Dohme, Roche, Servier, Sanofi‐Aventis, and Novartis. JRC has consulted for and/or given educational talks for Merck Sharp and Dohme, Amgen, Actavis, Bayer and Sanofi‐Aventis.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85126197373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126197373&partnerID=8YFLogxK

U2 - 10.1002/jbmr.4530

DO - 10.1002/jbmr.4530

M3 - Letter

C2 - 35195305

AN - SCOPUS:85126197373

SN - 0884-0431

VL - 37

SP - 1075

EP - 1076

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

IS - 5

ER -